Clonal Neoantigen: Emerging “Mechanism-based” Biomarker of Immunotherapy Response

Clonal Neoantigen: Emerging “Mechanism-based” Biomarker of Immunotherapy Response

Clonal mutations represent the initiating molecular defects related to cellular transition of a normal phenotype to a malignant phenotype. Molecular genomic assessment utilizing next generation and whole exome sequencing is now being increasingly applied to biomarker determination to refine the use...

Full description

Bibliographic Details
Main Authors: John Nemunaitis, Laura Stanbery, David Willoughby, Ernest Bognar, Scott Brun, Adam Walter, Bradley J. Monk, Rodney P. Rocconi, Khalil Choucair, Robert L. Coleman
Format: Article
Language:English
Published: MDPI AG 2023-11-01
Series:Cancers
Subjects:
clonal neoantigen
biomarker
immunotherapy
cancer
Vigil
Online Access:https://www.mdpi.com/2072-6694/15/23/5616

Similar Items

Similar Items